1. AHA: American Heart Association, 2002.
2. Marchioli R, Barzi F, Bomba E et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105(16):1897-903
3. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002; 56(8):365-79.
4. ESC: European Society of Cardiology, 2003.
5. WHO/FAO: World Health Organisation, 2003.
6. ISSFAL: International Society for the Study of Fatty Acids and Lipids, 2004.
7. EFSA Journal 2009; 7(9):1263.
8. Origasa H, Yokoyama M, Matsuzaki M, Saito Y, Matsuzawa Y; JELIS Investigators. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. Circ J 2010; 74(3):510-7.
9. Ghiasvand R, Djalali M, Djazayery SA et al. Effects of eicosapentaenoic acid (PLUSEPAâ) and vitamin E on the plasma levels of antioxidant vitamins and inflammatory markers, and on erythrocyte antioxidant enzyme activities, in male basketball players. Acta Medica Iranica 2009; 47(4): 269-274.
10. Bloomer RJ, Larson DE, Fisher-Wellman KH, Galpin AJ, Schilling BK. Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study. Lipids Health Dis 2009; 8:36.
11. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59(10):913-9.
|
|
12. Jazayeri S, Tehrani-Doost M, Keshavarz SA et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid (PLUSEPAâ) and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 2008; 42(3):192-8.
13. Jazayeri S, Keshavarz SA, Tehrani-Doost M, Djalali M, Hosseini M, Amini H, Chamari M, Djazayery A. Effects of eicosapentaenoic acid (PLUSEPAâ) and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res 2010; 178(1):112-5.
14. Rogers PJ, Appleton KM, Kessler D et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr 2008; 99(2):421-31.
15. Montgomery P, Richardson AJ. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst Rev 2008; (2):CD005169.
16. Gustafsson PA, Birberg-Thornberg U, Duchén K et al. EPA (PLUSEPAâ) supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr 2010; 99(10):1540-9.
17. Antypa N, Van der Does AJ, Smelt AH, Rogers RD. Omega-3 fatty acids (fish-oil) and depression-related cognition in healthy volunteers. J Psychopharmacol 2009; 23(7):831-40.
18. Simopoulos AP, Leaf A, Salem N Jr. Workshop statement on the essentiality of and recommended dietary intakes for Omega-6 and Omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 2000; 63(3):119-21.
19. Facchinetti F, Fazzio M, Venturini P. Polyunsaturated fatty acids and risk of preterm delivery. Eur Rev Med Pharmacol Sci 2005; 9(1):41-8.
20. Koletzko B, Cetin I, Brenna JT et al. International Society for the Study of Fatty Acids and Lipids. Dietary fat intakes for pregnant and lactating women. Br J Nutr 2007; 98(5):873-7. |
